Spectrum Solutions has acquired Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic lab, and Microarrays, Inc., a provider of array-based products used as biologic research tools.
 
Alimetrix, Inc.’s molecular laboratory capabilities and Microarrays, Inc.’s expertise in manufacturing array-based products, combined with Spectrum’s contract manufacturing services and biospecimen collection capabilities, creates a comprehensive suite of products and services.
 
Spectrum’s core business divisions include: LabServices, comprised of innovative assay development, contract manufacturing and clinical testing business support services.
 
SimplyTest, a family of validated, highly sensitive multiplex laboratory developed tests for both direct-to-consumer and physician-directed testing.
 
Compounding RX Pharmacy, an onsite, multi-state licensed patient-specific compounding pharmacy partner with direct-to-patient dispensing capabilities.
 
“The acquisitions of Alimetrix and Microarrays not only enhances Spectrum’s portfolio to include high-impact laboratory testing and custom assay services, it also serves to advance patient care and clinical research,” said Stephen Fanning, CEO at Spectrum Solutions. “Spectrum is now one step closer to its vision of developing a transformative, decentralized healthcare platform aimed at innovating the way biospecimens are collected and laboratory testing is conducted.”
 
“At Alimetrix and Microarrays, our mission has always been dedicated to performing work bigger than ourselves that enables positive change in the world through science. Joining forces with a scientifically committed company like Spectrum will extend and enhance our capabilities to the masses and help individuals and communities take control of their health,” said Joel Peek, President and Chief Science Officer at Alimetrix and Microarrays.